NCT02981888

Fecal Metabolome and the Intestinal Microbiota in Irritable Bowel Syndrome

Fecal Bile Acids, Fecal Short Chain Fatty Acids and the Intestinal Microbiota in Patients With Irritable Bowel Syndrome and Control Volunteers

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 100 (actual)
• Sponsor: Indiana University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to find out the relationship between the bile acids, fatty acids (fatty acids are part of the diet) and bacteria that are present in the intestines.

Detailed description

There is emerging evidence that alterations in bile acids and SCFA associated with IBS could be associated with changes in the gut microbiota. In addition to modulating levels of intraluminal organic acids, it has been hypothesized that gut microbiota may alter local immune responses, modulate visceral pain responses, and impair gut barrier function. Our overall goal is to investigate the relationship between fecal bile acids, SCFA and the gut microbiota in IBS. Results of this pilot study could reveal insights into the interplay of the gut microbiota and small molecule mediators of IBS to suggest targeted clinical strategies for improved diagnosis and management of this important syndrome. AIM 1: Test the hypothesis that fecal organic acids (SFCA and bile acids) and fecal microbiota play an important role in IBS. AIM 2: Test the hypothesis that there is association between colonic transit and fecal microbiota in IBS

Conditions

• IBS

Interventions

Type	Name	Description
RADIATION	X-Ray	X-ray of the abdomen will be performed to assess colonic transit

Timeline

• Start date: 2016-07-01
• Primary completion: 2023-04-27
• Completion: 2023-04-27
• First posted: 2016-12-05
• Last updated: 2024-04-29

Locations

1 site across 1 country: United States